**AbbVie Reports Strong Growth in Neuroscience Segment for 2025**
AbbVie (ABBV) announced that its neuroscience segment accounted for over 17% of total revenues in the first nine months of 2025, driven by double-digit sales increases across key offerings like Botox Therapeutic, Vraylar, Qulipta, and Ubrelvy. Notably, the Parkinson’s disease therapy Vyalev generated $299 million in sales during this period. The company projects neuroscience sales to reach $10.7 billion by year-end, reflecting a 19% increase from 2024, with estimates slightly higher at $10.8 billion.
The expansion plans include a regulatory filing with the FDA for tavapadon, an oral therapy for Parkinson’s disease, expected to launch later this year. AbbVie is also investing in pipeline expansion, acquiring Gilgamesh Pharmaceuticals’ psychedelic drug candidate, bretisilocin, currently in mid-stage trials for major depressive disorder.
AbbVie currently trades at a price-to-earnings ratio of 21.41, above the industry average of 19.26, amid consistent earnings estimates of $10.64 for 2025.
